Skip to main content
. 2023 May 19;77(6):816–826. doi: 10.1093/cid/ciad294

Figure 2.

Figure 2.

Description of cohort exposures. Top 20 most abundant autoimmune diseases (AID) (A) and immunosuppressant exposures (B) prior to diagnosis of laboratory-confirmed coronavirus disease 2019. “Other selective immunosuppressants” include selective immunosuppressants that are not interleukin inhibitors, JK inhibitors, TNF alpha inhibitors, or monoclonal antibodies. “Other antineoplastic agents” includes monoclonal antibodies, Cancer Drugs L01 Other Cancer Therapies defined using World Health Organization Anatomical Therapeutic Chemistry Class L01 products that were not anthracyclines, checkpoint inhibitors, cyclophosphamide, or protein kinase inhibitors. "L01 other" includes other cancer therapies include therapies that are not anthracyclines, checkpoint inhibitors, cyclophosphamide, or protein kinase inhibitors. (C) Number of patients with single/multiple AID and patients with single/multiple immunosuppressant exposures. Abbreviations: JAK, Janus Kinase; PK, protein kinase; TNF, tumor necrosis factor.